Afzal A, Muanprasat C, Khawar MB. Prognostic role of histone deacetylase 10 in colorectal cancer: Strengths and gaps. World J Gastroenterol 2025; 31(40): 111951 [DOI: 10.3748/wjg.v31.i40.111951]
Corresponding Author of This Article
Chatchai Muanprasat, Professor, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, 270 Rama VI Road/Phutthamonthon 4 Road, Bangplee 10540, Samut Prakan, Thailand. chatchai.mua@mahidol.ac.th
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 28, 2025 (publication date) through Oct 30, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Afzal A, Muanprasat C, Khawar MB. Prognostic role of histone deacetylase 10 in colorectal cancer: Strengths and gaps. World J Gastroenterol 2025; 31(40): 111951 [DOI: 10.3748/wjg.v31.i40.111951]
World J Gastroenterol. Oct 28, 2025; 31(40): 111951 Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111951
Prognostic role of histone deacetylase 10 in colorectal cancer: Strengths and gaps
Ali Afzal, Chatchai Muanprasat, Muhammad Babar Khawar
Ali Afzal, University of Chinese Academy of Sciences, Beijing 100049, China
Ali Afzal, Muhammad Babar Khawar, School of Basic Medical Sciences, School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, Jiangsu Province, China
Chatchai Muanprasat, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Bangplee 10540, Samut Prakan, Thailand
Co-corresponding authors: Chatchai Muanprasat and Muhammad Babar Khawar.
Author contributions: Afzal A and Khawar MB were primarily responsible for drafting this letter; Khawar MB provided valuable suggestions; Muanprasat C meticulously revised the letter; Muanprasat C and Khawar MB made equal contributions as co-corresponding authors; all authors approved the final version to publish.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chatchai Muanprasat, Professor, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, 270 Rama VI Road/Phutthamonthon 4 Road, Bangplee 10540, Samut Prakan, Thailand. chatchai.mua@mahidol.ac.th
Received: July 14, 2025 Revised: July 29, 2025 Accepted: September 16, 2025 Published online: October 28, 2025 Processing time: 105 Days and 14.7 Hours
Abstract
Histone deacetylase 10 (HDAC10) is emerging as a critical modulator of tumor immunity, chemoresistance, and transcriptional plasticity in colorectal cancer. Its suppression has been linked to altered CD8+ T cell activity, increased p53 expression, and reduced programmed death ligand 1 levels, suggesting a potential role in immune evasion. However, mechanistic understanding of HDAC10’s selective function, especially in shaping the tumor microenvironment, remains limited. We advocate for targeted investigations using isoform-selective inhibitors, functional in vivo studies, and immune subset profiling to clarify HDAC10’s therapeutic relevance in colorectal cancer.
Core Tip: Histone deacetylase 10 (HDAC10) plays a multifaceted role in colorectal cancer by modulating immune evasion, chemoresistance, and transcriptional regulation. Its suppression influences CD8⁺ T cell activation, enhances p53 expression, and reduces programmed death ligand 1 levels, suggesting critical involvement in tumor-immune interactions. Selective HDAC10 inhibition, unlike pan-HDAC blockade, may offer targeted therapeutic benefit, particularly in microsatellite-stable tumors. Further in vivo studies and mechanistic dissection of HDAC10-p53-programmed death ligand 1 signaling are essential to harness its full potential in reshaping the tumor microenvironment and improving immunotherapy outcomes.
